Literature DB >> 16360010

Transplantation for liver tumors.

Jacques Belghiti1.   

Abstract

Currently, the primary use of liver transplantation in the setting of malignancy is in patients with hepatocellular carcinoma, with generally accepted criteria for transplantation consisting of the presence of one nodule less than 5 cm or two of three nodules each less than 3 cm in the absence of detectable vascular invasion. In some patients and settings, surgical resection before transplantation is an emerging, promising option. There is no clear beneficial role of transplantation in patients with resectable or unresectable cholangiocarcinoma, except in selected patients with unresectable disease that is associated with primary sclerosing cholangitis. While good survival results have been achieved with transplantation in patients with epithelioid hemangioendothelioma of the liver, the long-term survival of some patients without any radical treatment leaves the benefit of transplantation unclear. Transplantation would appear to benefit some patients with unresectable liver metastases from neuroendocrine tumors; those who present with non-neuroendocrine liver metastases are not considered candidates for transplantation.

Entities:  

Mesh:

Year:  2005        PMID: 16360010     DOI: 10.1053/j.seminoncol.2005.07.023

Source DB:  PubMed          Journal:  Semin Oncol        ISSN: 0093-7754            Impact factor:   4.929


  4 in total

1.  Surgical treatment for early hepatocellular carcinoma: comparison of resection and liver transplantation.

Authors:  Jian Zhou; Zheng Wang; Shuang-Jian Qiu; Xiao-Wu Huang; Jian Sun; Wen Gu; Jia Fan
Journal:  J Cancer Res Clin Oncol       Date:  2010-02-11       Impact factor: 4.553

2.  Transplantation vs resection for hepatocellular carcinoma with compensated liver function after downstaging therapy.

Authors:  Jian-Yong Lei; Lu-Nan Yan; Wen-Tao Wang
Journal:  World J Gastroenterol       Date:  2013-07-21       Impact factor: 5.742

3.  MELD score and AST-to-platelet ratio index (APRI) predict long-term survival in patients with a small hepatocellular carcinoma following non-transplant therapies: a pilot study.

Authors:  Joy Sarkar; Thomas DeLeon; Linda L Wong
Journal:  Hepatoma Res       Date:  2017-05-09

4.  Preclinical and post-treatment changes in the HCC-associated serum proteome.

Authors:  D G Ward; Y Cheng; G N'Kontchou; T T Thar; N Barget; W Wei; A Martin; M Beaugrand; P J Johnson
Journal:  Br J Cancer       Date:  2006-10-24       Impact factor: 7.640

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.